ImmunityBio
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ImmunityBio generated cash of -$366,757,000, which is less than the previous year. Cash used in financing activities reached the amount of $558,341,000 last year. Net change in cash is therefore $160,822,000.
Cash Flow
| 2014 | -5.35M | -299K | 64.40M |
|---|---|---|---|
| 2015 | -25.30M | -175.22M | 317.33M |
| 2016 | -38.59M | -113.67M | -15.56M |
| 2017 | -48.78M | 99.55M | -34.98M |
| 2018 | -63.38M | 57.10M | -771K |
| 2019 | -152.10M | 18.55M | 114.27M |
| 2020 | -171.72M | -19.81M | 150.67M |
| 2021 | -274.41M | -84.88M | 505.44M |
| 2022 | -337.50M | 27.29M | 233.61M |
| 2023 | -366.75M | -30.47M | 558.34M |
IBRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 104.96M | 181.28M | 35.09M | 75.98M | 95.27M | 23.87M | 8.08M | 175.90M | 59.10M | 350K |
Operating activities | ||||||||||
Net income | -583.19M | -417.32M | -349.84M | -224.18M | -160.15M | -96.22M | -96.42M | -120.80M | -236.87M | -6.21M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 18.51M | 18.26M | 14.23M | 12.73M | 14.04M | 9.55M | 5.56M | 3.60M | 1.47M | 128K |
Stock-based compensation expense | 49.16M | 40.17M | 57.18M | 2.18M | 3.42M | 0 | 36.99M | 0 | 211.22M | 0 |
| Deferred income tax benefit | 49.16M | 40.17M | 57.18M | 2.18M | 3.42M | 0 | 36.99M | 0 | 211.22M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.45M | 75K | 95K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -6.47M | 8M | -3.71M | 2.57M | 1.18M | -1.1M | 150K | 888K | 627K | -347K |
Cash generated by operating activities | -366.75M | -337.50M | -274.41M | -171.72M | -152.10M | -63.38M | -48.78M | -38.59M | -25.30M | -5.35M |
Investing activities | ||||||||||
Purchases Of Investments | -10.35M | -34.31M | -141.75M | -91.76M | -87.19M | -95.49M | -119.85M | -272.99M | -198.06M | 0 |
Investments In Property Plant And Equipment | -30.58M | -99.39M | -33.56M | -1.66M | -4.28M | -13.10M | -34.81M | -6.56M | -2.24M | -299K |
Acquisitions Net | 0 | -1M | 20.49M | 8K | 200K | 412K | -32K | -137K | -1.81M | 0 |
Cash generated by investing activities | -30.47M | 27.29M | -84.88M | -19.81M | 18.55M | 57.10M | 99.55M | -113.67M | -175.22M | -299K |
Financing activities | ||||||||||
Common Stock Issued | 110.10M | 60.42M | 164.53M | 86.30M | 30M | 57K | 1.21M | 1.42M | 324.67M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -4.06M | -503K | -2.50M | -228K | -15.22M | -15.84M | -4.79M | 0 |
Repayments of term debt | 258.62M | 174.06M | -338.5M | -3.94M | 47.67M | -477K | -19.93M | -32K | -132K | -53K |
Cash used in financing activities | 558.34M | 233.61M | 505.44M | 150.67M | 114.27M | -771K | -34.98M | -15.56M | 317.33M | 64.40M |
Net Change In Cash | 160.82M | -76.31M | 146.18M | -40.88M | -19.29M | -7.05M | 15.78M | -167.82M | 116.80M | 58.75M |
Cash at end of period | 265.45M | 104.96M | 181.28M | 35.09M | 75.98M | 16.82M | 23.87M | 8.08M | 175.90M | 59.10M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |